Kyverna Therapeutics, INC 8-K filings

Kyverna Therapeutics has appointed Mert Aktar, a seasoned biotechnology executive, to its Board of Directors, enhancing its expertise in corporate strategy and cell therapy development.

Kyverna Therapeutics has appointed Warner Biddle as its new CEO and Christi Shaw to its Board of Directors, marking a significant leadership transition for the company.

Kyverna Therapeutics announced positive clinical trial updates for its lead candidate KYV-101, along with its second quarter 2024 financial results, showing increased net loss but strong cash reserves.

Kyverna Therapeutics has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA for its KYV-101 therapy in the treatment of refractory stiff-person syndrome.

Kyverna Therapeutics shared an update on its KYV-101 CAR T-cell therapy, highlighting promising safety and efficacy data across multiple autoimmune diseases at an industry symposium.

Kyverna Therapeutics announced its first quarter 2024 financial results and provided a business update, highlighting clinical advancements and a strengthened balance sheet following its recent IPO.

Kyverna Therapeutics announced its full year 2023 financial results and provided a business update, highlighting clinical advancements and a strengthened financial position.

Kyverna Therapeutics successfully closed its initial public offering, raising $366.9 million, and amended its certificate of incorporation and bylaws to reflect its new status as a public company.